Research Analysts Set Expectations for AUTL FY2024 Earnings

Autolus Therapeutics plc (NASDAQ:AUTL) – Stock analysts at William Blair reduced their FY2024 EPS estimates for Autolus Therapeutics in a research note issued on Tuesday, November 12th. William Blair analyst M. Phipps now forecasts that the company will earn ($1.09) per share for the year, down from their prior forecast of ($0.92). The consensus estimate for Autolus Therapeutics’ current full-year earnings is ($0.84) per share. William Blair also issued estimates for Autolus Therapeutics’ Q4 2024 earnings at ($0.33) EPS, Q1 2025 earnings at ($0.24) EPS, Q2 2025 earnings at ($0.25) EPS, Q4 2025 earnings at ($0.20) EPS, FY2026 earnings at ($0.76) EPS and FY2027 earnings at ($0.53) EPS.

Autolus Therapeutics (NASDAQ:AUTL) last released its earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same period in the prior year, the business posted ($0.26) EPS.

A number of other analysts have also weighed in on the stock. Redburn Atlantic upgraded shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 target price on the stock in a research note on Friday. Needham & Company LLC restated a “buy” rating and issued a $9.00 price objective on shares of Autolus Therapeutics in a report on Monday, November 11th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $9.45.

Autolus Therapeutics Price Performance

Shares of NASDAQ AUTL opened at $3.08 on Friday. The company has a market cap of $819.56 million, a price-to-earnings ratio of -2.55 and a beta of 2.04. The stock’s 50-day moving average is $3.91 and its two-hundred day moving average is $3.98. Autolus Therapeutics has a 1-year low of $2.94 and a 1-year high of $7.45.

Hedge Funds Weigh In On Autolus Therapeutics

Several hedge funds have recently made changes to their positions in AUTL. ProShare Advisors LLC purchased a new position in Autolus Therapeutics during the 2nd quarter worth approximately $43,000. Capstone Investment Advisors LLC acquired a new position in shares of Autolus Therapeutics in the 3rd quarter valued at $51,000. Daiwa Securities Group Inc. raised its position in Autolus Therapeutics by 2,659.7% in the 2nd quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company’s stock valued at $55,000 after purchasing an additional 15,293 shares during the last quarter. Herbst Group LLC purchased a new position in Autolus Therapeutics during the 3rd quarter worth $91,000. Finally, Bayesian Capital Management LP purchased a new stake in shares of Autolus Therapeutics in the first quarter valued at about $100,000. Hedge funds and other institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.